Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
03/26/03	SEK 0.8500	-0.35%	6,66,382
02/26/02	SEK 0.8530	+5.57%	14,11,147
01/26/01	SEK 0.8080	+1.00%	7,07,328
31/26/31	SEK 0.8000	-4.76%	6,80,209
28/26/28	SEK 0.8400	-0.59%	16,76,168

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm 09:30:00 03/09/2026 pm IST			5-day change	1st Jan Change
0.8500 ^SEK	-0.35%		+0.59%	+2.53%

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW

Market Cap	17Cr 1.8Cr 1.55Cr 1.46Cr 1.33Cr 2.49Cr 170.47Cr 2.51Cr 6.71Cr 87Cr 6.77Cr 6.62Cr 280.57Cr	P/E 2026 *	-3.15x	P/E 2027 *	-2.24x
Enterprise Value	16Cr 1.64Cr 1.41Cr 1.32Cr 1.21Cr 2.26Cr 154.64Cr 2.27Cr 6.08Cr 79Cr 6.14Cr 6.01Cr 254.51Cr	EV / Sales 2026 *	4.98x	EV / Sales 2027 *	-
Free-Float	75.07%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed

20/08	Alzinova AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	RX Securities reiterates buy on Alzinova, justified value SEK 3.50	FW
20/08	Alzinova reports reduced operating loss	FW
20/08	Calendar Thursday, August 20	FW
24/06	Alzinova AB and Fujirebio Enter Letter of Intent for Potential Commercialization of Blood-Based Alzheimer?S Diagnostic Test	CI
24/06	Alzinova Inks Nonbinding Deal with Fujirebio for Potential Alzheimer's Blood-based Diagnostic Test	MT
24/06	RX Securities reiterates buy on Alzinova after letter of intent with Fujirebio	FW
24/06	Alzinova signs non-binding letter of intent with Fujirebio on Alzheimer's diagnostics	FW
12/06	Alzinova raises SEK15.3m from warrants: underwriting not required	FW
08/06	Alzinova raises SEK 15.2 million before issuance costs	FW
26/05	Calendar Tuesday May 26	FW
25/05	Calendar Tuesday May 26	FW
21/05	Alzinova secures 80 percent of TO4 warrants	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation : Alzinova AB

Chart: Alzinova AB

Latest news : Alzinova AB

Analysts' recommendations : Alzinova AB

Press Releases : Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors : Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

24/08	Alzinova: Diagnostics readout next, partner process delayed – Q2 review	AQ
20/08	Alzinova (Q2 Review): Capitalizing on diagnostics opportunities	AQ
20/08	Alzinova publishes interim report for the period January - June 2026	AQ
07/07	BioVal™ analysis of Alzinova's ALZ-101 – rNPV of SEK 7.1B	AQ
24/06	Alzinova: Newsflow update – diagnostic optionality and TO4 proceeds	AQ

1 day	-0.35%
1 week	+0.59%
Current month	+6.25%
1 month	-22.45%
3 months	+93.18%
6 months	+45.05%
Current year	+2.53%

1 week	0.77	0.9
1 month	0.75	1.14
Current year	0.38	1.61
1 year	0.38	2.28
3 years	0.38	4.62
5 years	0.38	8.7
10 years	0.38	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	-	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	-0.35%	+0.59%	-41.78%	-72.97%	1.8Cr
LONZA GROUP AG	-0.24%	-1.09%	+2.00%	+17.50%	5.01TCr
REVOLUTION MEDICINES, INC.	+0.51%	-4.82%	+429.24%	+524.76%	4.48TCr
IQVIA HOLDINGS INC.	+2.44%	+2.82%	+46.12%	+22.13%	4.34TCr
BEONE MEDICINES AG	+0.05%	-2.83%	+7.64%	+76.70%	4.11TCr
CELLTRION, INC.	+0.43%	-3.26%	+14.75%	+49.08%	3.29TCr
ASCENDIS PHARMA A/S	+1.21%	+8.25%	-	-	1.76TCr
MEDPACE HOLDINGS, INC.	-0.22%	-3.16%	+23.06%	+123.39%	1.66TCr
EUROFINS SCIENTIFIC SE	+0.93%	+0.88%	+19.64%	+29.70%	1.46TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+0.36%	-1.16%	+80.48%	+43.41%	1.39TCr
Average	+0.49%	-0.46%	+64.57%	+90.41%	2.75TCr
Weighted average by Cap.	+0.58%	-1.13%	+92.94%	+128.97%

	2026 *	2027 *
Net sales	3.14Cr 32.82L 28.24L 26.5L 24.25L 45.25L 31Cr 45.61L 1.22Cr 16Cr 1.23Cr 1.21Cr 51Cr	-
Net income	-44.5L -5L -4L -4L -3L -6L -4.4Cr -6L -17.33L -2.25Cr -17.5L -17.11L -7.25Cr	-7.7Cr -80.62L -69.36L -65.09L -59.55L -1.11Cr -76Cr -1.12Cr -3Cr -39Cr -3.03Cr -2.96Cr -125.43Cr
Net Debt	-1.6Cr -16.75L -14.41L -13.53L -12.37L -23.1L -16Cr -23.28L -62.31L -8.09Cr -62.9L -61.53L -26Cr	-1.9Cr -19.89L -17.12L -16.06L -14.69L -27.43L -19Cr -27.64L -73.99L -9.61Cr -74.7L -73.07L -31Cr